Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 2 of 18 for:    cytosorb

Use of Extracorporeal Treatment With the Cytosorb-Adsorber for the Reduction of SIRS in Heart Surgery Patients (CASHSP)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by Dr. Martin Sauer, MD, University of Rostock
Sponsor:
Information provided by (Responsible Party):
Dr. Martin Sauer, MD, University of Rostock
ClinicalTrials.gov Identifier:
NCT02265419
First received: October 9, 2014
Last updated: April 19, 2017
Last verified: April 2017
  Purpose

Heart-surgery with the use of a heart-lung-machine can trigger the development of a full-blown SIRS (Systemic Inflammatory Response Syndrom) with multi organ failure and severe sepsis in the course of disease.

For the treatment of full-blown SIRS extracorporeal treatment like the Cytosorb-Adsorber are in clinical testing. The Cytosorb-Adsorber is a CE-signed medical device with approval for the treatment of severe sepsis and hyperinflammation. The adsorber remove not-specific cytokines and other inflammation mediators from the patients blood.

In this study (as a case-observation and compassionate use) the effect of extracorporeal treatment with the Cytosorb-Adsorber for the reduction of postoperative hyperinflammation and SIRS after heart-surgery with use of a heart-lung-machine will be observed.

The aim of the study is recording the influence of the treatment with the Cytosorb-Adsorber on the course of hyperinflammation and multi organ failure in comparison with a historic control group.


Condition Intervention
Multiple Organ Failure
Device: Extracorporeal treatment with the Cytosorb adsorber

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Case-observation and Compassionate Use: Use of Extracorporeal Treatment With the Cytosorb-Adsorber for the Reduction of Postoperative Hyperinflammation and SIRS After Heart-surgery With the Use of a Heart-lung-machine

Resource links provided by NLM:


Further study details as provided by Dr. Martin Sauer, MD, University of Rostock:

Primary Outcome Measures:
  • mean SOFA [ Time Frame: day 7 ]
    A significant difference in the mean-SOFA (Sequential Organ Failure Assessment)-score between the Cytosorb-group and the historic control group after 7 days.


Secondary Outcome Measures:
  • 30- and 90-day survival [ Time Frame: day 30, day 90 ]
    Observation time 90 days.

  • time of respirator-therapy [ Time Frame: day 90 ]
    Observation time 90 days.

  • length of ICU stay [ Time Frame: day 90 ]
    Observation time 90 days.

  • dosage of vasopressors on the days 1, 2 and 3. [ Time Frame: day 1, 2 and 3 ]
    Use of Vasopressors are monitored.


Estimated Enrollment: 10
Study Start Date: October 2014
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cytosorb group
Extracorporeal treatment with the Cytosorb adsorber for 24 hours after heart surgical operation.
Device: Extracorporeal treatment with the Cytosorb adsorber
The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.

Detailed Description:

All patients underlying heart surgery with the use of a heart-lung-machine and fullfilling of the inclusion-criteria should be sreened for the study. The study take place on two surgical intensive care units (PIT I and PIT II) of the university hospital Rostock, Germany. The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after end of the operation if written informed consent was obtained from all participants or from the patients` representatives if direct consent could not be received. The extracorporeal treatment duration will be 24 hours and the observation time 90 days.

The aim of the study is recording the influence of the treatment with the Cytosorb-Adsorber on the course of hyperinflammation and multi organ failure in comparison with a historic control group. The main-criterion is a significant difference in the mean-SOFA (Sequential Organ Failure Assessment)-score between the Cytosorb-group and the historic control group after 7 days. Beside criterions are the 30- and 90-day survival, time of respirator-therapy, length of ICU stay, severity of the Critical Illness Polyneuropathy and dosage of vasopressors on the days 1, 2 and 3.

From all patients basic demographic information, illness severity (APACHE II, SOFA scores), microbiological results, pre-morbidity, and clinical outcome for study cohort will recorded. At the days 1-4, 7, 14, 30 and before/after the extracorporeal treatment the patients will screened for clinical and immunological data: hemodynamic, inflammation, coagulation, hemolysis, temperature, organ function blood parameters and cytokines. "Day 1" was defined as the day of the beginning of the extracorporeal treatment. At days 1, 2 and 7 hemodynamic monitoring will done with the PiCCO-System (PULSION Medical Systems, Feldkirchen, Germany). For dynamic measurement of the liver function will used the LiMON-System (based on the indocyanin green plasma disappearance rate, PULSION) on the days 1, 2 and 7.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • After heart surgery with heart-lung-machine
  • 2 or more positive SIRS criterions within 6 hours postoperative
  • need of > 1,9 liter kristalloids within 6 hours postoperative
  • centralvenous oxygen saturation >75% within 6 hours postoperative
  • need of vasopressors (≥0,06 µg/Kg/Min) within 6 hours postoperative

Exclusion Criteria:

  • Bleeding
  • Thrombocyten < 20.000 /µl, INR>3,0
  • HIV-Test positive
  • Hepatitis C positive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02265419

Contacts
Contact: Martin Sauer, PD Dr. 49 381 4946409 martin.sauer@uni-rostock.de
Contact: Johannes Ehler, Dr. 49 381 4946401 johannes.ehler@med.uni-rostock.de

Locations
Germany
Intensive Care Units PIT 1+2, University hospital Rostock Recruiting
Rostock, Germany, 18055
Contact: Martin Sauer, PD Dr.    49 381 4946434      
Sponsors and Collaborators
University of Rostock
Investigators
Principal Investigator: Martin Sauer, PD Dr. University of Rostock, University Hospital, Intensive Care, Schillingallee 35, 18055 Rostock, Germany
  More Information

Responsible Party: Dr. Martin Sauer, MD, PD Dr., University of Rostock
ClinicalTrials.gov Identifier: NCT02265419     History of Changes
Other Study ID Numbers: A 2014-0064
Study First Received: October 9, 2014
Last Updated: April 19, 2017

Keywords provided by Dr. Martin Sauer, MD, University of Rostock:
hyperinflammation, Cytosorb

Additional relevant MeSH terms:
Multiple Organ Failure
Shock
Pathologic Processes

ClinicalTrials.gov processed this record on May 25, 2017